Daptomycin use in a neonate: Serum level monitoring and outcome

American Journal of Perinatology

Volumn 27, Issue 5, 2010, Pages 421-424

  Sarafidis, Kosmas ^a   Iosifidis, Elias ^a   Gikas, Evangelos ^b   Tsivitanidou, Maria ^c   Drossou Agakidou, Vassiliki ^a   Roilides, Emmanuel ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Goulandris Natural History Museum   (Greece)

^c Aristotle University of Thessaloniki   (Greece)

Author keywords

Daptomycin; Drug monitoring; Enterococcal bacteremia; Neonate

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; CEFEPIME; CEFUROXIME AXETIL; DAPTOMYCIN; GENTAMICIN; LINEZOLID; NITRIC OXIDE; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; ANTIINFECTIVE AGENT;

ARTICLE; BLOOD CULTURE; CASE REPORT; CHORIOAMNIONITIS; CONTINUOUS INFUSION; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROCOCCUS FAECIUM; FEMALE; GENERAL CONDITION IMPROVEMENT; GRAM POSITIVE INFECTION; HUMAN; NEWBORN; NEWBORN SEPSIS; NONHUMAN; OUTCOME ASSESSMENT; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY FAILURE; SIDE EFFECT; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT DURATION; BLOOD; GRAM-POSITIVE BACTERIAL INFECTIONS; MALE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; TREATMENT OUTCOME;

EID: 77952936197     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0029-1243370     Document Type: Article

References (10)

1. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology 2008 81 79-91
2. Ardura M I., Mejías A, Katz K S., Revell P, McCracken G H. Jr, Snchez P J. Daptomycin therapy for invasive gram-positive bacterial infections in children. Pediatr Infect Dis J 2007 26 1128-1132
3. Abdel-Rahman S M., Benziger D P., Jacobs R F., Jafri H S., Hong E F., Kearns G L. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 2008 27 330-334
4. Cohen-Wolkowiez M, Smith P B., Benjamin D K. Jr, Fowler V G. Jr, Wade K C. Daptomycin use in infants: report of two cases with peak and trough drug concentrations. J Perinatol 2008 28 233-234
5. Sakoulas G, Golan Y, Lamp K C., Friedrich L V., Russo R. Daptomycin in the treatment of bacteremia. Am J Med 2007 120 (10 Suppl 1) S21-S27
6. Mohr J F., Friedrich L V., Yankelev S, Lamp K C. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009 33 543-548
7. Dvorchik B, Arbeit R D., Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004 48 2799-2807
8. Benvenuto M, Benziger D P., Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006 50 3245-3249
9. Castanheira M, Jones R N., Sader H S. Update of the in vitro activity of daptomycin tested against 6710 gram-positive cocci isolated in North America (2006). Diagn Microbiol Infect Dis 2008 61 235-239
10. Malli E, Spiliopoulou I, Kolonitsiou F et al. In vitro activity of daptomycin against gram-positive cocci: the first multicentre study in Greece. Int J Antimicrob Agents 2008 32 525-528